Expert Financial Analysis and Reporting

Key Investment Considerations   Cytokinetics Has Two Key Drugs in Phase IIb Development Cytokinetics (CYTK) has been the pioneer in developing new drugs based on muscle biology which modulate the mechanics of muscle, particularly those which affect contractility. It has two late stage drugs that will be reading out data on critical phase IIb trials […]

Investment Thesis We are now nearing the long awaited launch of Surfaxin. During the recent conference call on results for 4Q, 2012, the Company reaffirmed that it is anticipating the launch of Surfaxin in 2Q, 2013. The company through a debt deal with Deerfield Capital recently brought in $10 million of cash and will receive […]

BromSite Results are Strikingly Positive in First Phase III Trial InSite Vision (INSV.OB) just announced top-line results from its first phase III trial of BromSite which is indicated for the reduction of inflammation and pain after cataract surgery. BromSite is the anti-inflammatory drug bromfenac delivered with the Company’s proprietary DuraSite drug delivery system; it was […]

Introduction NovaBay (NBY) is focused on the development of novel anti-microbial products that are topically applied as gels, liquid solutions and instillates. By replicating the mechanism of action used by the body’s innate immune system, NovaBay has created products that hold the potential to treat bacteria and microbes resistant to currently used drugs and as […]

Investment Summary and Conclusion I began recommending Trius (TSRX) with an initiation of coverage report that was published in May of 2012 and I continue to recommend the stock. That report and three subsequent updates explain my thinking on the clinical and commercial potential of its lead drug tedizolid, an antibiotic that is effective against […]

Investment Thesis I continue with my buy recommendation on Cadence Pharmaceuticals (CADX). I believe that there is a high probability for an important near term catalyst that could give the stock a nice boost. This would be a legal settlement with Exela Pharmaceuticals, which is challenging Ofirmev’s patents. If it is similar to a settlement […]

Adam Feuerstein of The Street.com and I crossed swords after I wrote an article in response to a very negative and stridently worded blog that he posted on Northwest Biotherapeutics (NWBO). I disagreed with his analysis (a one or two page blog) that accused the company of purposely deceiving investors and felt that it should not go unchallenged. I wrote a response that was published on Seeking and my website. Mr. Feurstein promptly responded with another blog called Why Seeking Alpha’s Larry Smith Is Wrong Again About Northwest Bio.

Purpose of this Report I have undertaken a point by point examination of a negative blog on Northwest Biotherapeutics (NWBO) by Adam Feuerstein of The Street.Com. I ordinarily don’t respond to comments that other bloggers make on companies. However, in this case Mr. Feuerstein accused the company of purposely deceiving investors on the results of […]

Introduction Over the last year, I have written seven articles on Transcept (TSPT) and if you would like to have a more in-depth view of my thinking on the product. I would urge you to review those articles either on Seeking Alpha or my website SmithOnStocks.com. This report focuses primarily on the progress of the […]

Investment Perspective Discovery’s (DSCO) stock has languished since it announced before the opening on October 24, 2012 that it was delaying the launch of Surfaxin from November of 2012 until 2Q, 2013. The stock had closed at $2.75 on October 23 and it then closed on October 24 at $2.71. The initial investor reaction appeared […]